Needham Reiterates Hold Rating on Teleflex (TFX)

Needham analyst Mike Matson reiterated a Hold rating on Teleflex (NYSE: TFX).

The analyst commented: "TFX completed its acquisition of Biotronik's Vascular Intervention business on 7/1/25, and we update our model to reflect the acquisition. We raise our 2025E and 2026E revenue to account for revenue from the deal, and we raise our 2025E and 2026E EPS to account for accretion from the deal. We maintain our Hold rating given that there is potentially ~12 months before TFX's separation is completed and there is greater visibility into revenue growth rates of the two businesses (RemainCo and NewCo)."

For an analyst ratings summary and ratings history on Teleflex click here. For more ratings news on Teleflex click here.

Shares of Teleflex closed at $116.67 yesterday.

You May Also Be Interested In